For GEPIA validation analysis, most of the FA metabolic enzymes, including ACLY, FASN, CPT1A, HADHA, HADHB, and ACAT1, showed the consistent prognosis (OS) with the same follow-up period (150 months) in another 516 ccRCC patients (Figure S3). The gene discussed is FASN; the disease is nonpapillary renal cell carcinoma.